Data Bridge Market Research analyses that the non-24-hour sleep-wake disorder drug will exhibit a CAGR of around 5.2% for the forecast period of 2021-2028. Rising government policies and initiatives to offer a fund to many research institute and pharmaceuticals companies, increasing prevalence of circadian rhythm sleep disorder cases worldwide, increase demand of disease specific treatment, and increased expenditure for the development of healthcare infrastructure are the major factors attributable to the growth of non-24-hour sleep-wake disorder drug market.